100 Clinical Results associated with Apollo Therapeutics Group Ltd.
0 Patents (Medical) associated with Apollo Therapeutics Group Ltd.
01 May 2024·C108. MECHANISMS OF LUNG INFLAMMATION AND INFECTION
A Rhinovirus VP0 Vaccine Induces Cross-reactive Type 1 Immunity and Promotes Lymphocyte Activation and Maturation
Author: Edwards, M.R. ; Shaw, S. ; Johnston, S.L. ; Patel, N.D. ; Pyle, C.J.
01 May 2023·D13. INNATE AND ADAPTIVE IMMUNE MECHANISMS REGULATING LUNG DISEASE
A Rhinovirus-A16 VP0 Vaccine Induces Homotypic Humoral and Cellular Immunity, and Following Heterotypic Rhinovirus-A01 Infection, Accelerates Virus Clearance and Induces Cross-strain IFN-γ T Cell and Neutralising Antibody Responses
Author: Shaw, S. ; Edwards, M.R. ; Wang, Z. ; Patel, N.D. ; Tregoning, J.S. ; Hamblin, P. ; Johnston, S.L. ; Pyle, C.J. ; Butt, R.
100 Deals associated with Apollo Therapeutics Group Ltd.
100 Translational Medicine associated with Apollo Therapeutics Group Ltd.